Biotech drugmaker Amgen, the company said on Thursday that the U.S. Food and Drug Administration has approved its bone drugs XGEVA of a new use.
The company is headquartered in Thousand Oaks, California, said it can now be used to treat a rare disease, giant cell tumor, surgery is not the actual market XGEVA.
It usually affects people aged 20-40. Tumor destruction of bone, often causing a fracture, can lead to severe pain, joint dysfunction, deformity or amputation.
Newly approved for use in adults and adolescents who have stopped growing.
Testing found that a quarter of biological drugs are injected to help patients condition, but it can cause side effects, including a plurality of parts of the body pain, fatigue, nausea, and damage to the jaw.
XGEVA is approved for preventing bone damage solid tumors.
 



Other News:
FDA backs new for Amgen drug for rare bone tumors
Seatbelts could have prevented 3 Boston U deaths
Crackdown filling NKorean prisons with defectors
Wash. House passes estate tax fix
Asian markets down on concern about Japan, US
EU worried by violence in Turkey, calls for inquiries
A long awaited 'Final Fantasy' returns at E3
ISS urges Clearwire shareholders to vote against Sprint deal